Selinexor in multiple myeloma-Reference-Cited by-同舟云学术

Selinexor in multiple myeloma

Published:2024-03-03 Issue:4 Volume:25 Page:421-434
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Martino Enrica Antonia¹,Vigna Ernesto¹,Bruzzese Antonella¹,Labanca Caterina¹,Mendicino Francesco¹,Lucia Eugenio¹,Olivito Virginia¹,Zimbo Annamaria¹²,Torricelli Federica³,Neri Antonino⁴,Morabito Fortunato⁵,Gentile Massimo¹⁶

Affiliation:

1. Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy

2. UOC Laboratorio Analisi Cliniche, Biomolecolari e Genetica, Azienda Ospedaliera Annunziata, Cosenza, Italy

3. Laboratorio di Ricerca Traslazionale Azienda USL-IRCSS Reggio Emilia, Emilia-Romagna, Italy

4. Scientific Directorate IRCCS of Reggio Emilia, I-42123 Reggio Emilia, EmiliaRomagna, Italy

5. Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy

6. Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy

Funder

Progetto Ricerca Finalizzata

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2024.2333376

Reference100 articles.

1. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

2. The power of proteasome inhibition in multiple myeloma

3. Ixazomib for the treatment of multiple myeloma

4. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials

5. Immunomodulatory drugs (IMiDs) in multiple myeloma;Raza S;Curr Cancer Drug Targets,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple myeloma: signaling pathways and targeted therapy;Molecular Biomedicine;2024-07-04